[Movement Interpretation] ImmunityBio surged on September 17: Nant invests in PDSB + ANKTIVA

1. On September 14, Nant Capital led a PIPE financing for PDS Biotech of up to $22.3 million, with an initial closing raising about $11.3 million; ImmunityBio founder and Executive Chairman Patrick Soon-Shiong was appointed as a director of PDS Biotech, strengthening connections in the immunotherapy layout.
2. On September 11, ImmunityBio submitted a patent application aiming to combine ANKTIVA with checkpoint inhibitors, cancer vaccines, and engineered NK cells; in related non-small cell lung cancer data, the median survival was 21.1 months for patients with mild lymphocytopenia and 11.5 months for those with severe lymphocytopenia.
3. As of June 30, the company is mainly focused on the development and commercialization of next-generation immunotherapies, with its core Cancer BioShield platform based on IL-15 superagonist ANKTIVA, covering natural killer cells, cytotoxic T cells, and memory T cells.

(Disclaimer: This content is summarized from publicly available information by AI technology and is for reference only and does not constitute investment advice.)